Why Sensus Healthcare’s SkinCure resolution matters for superficial radiotherapy growth
Sensus settled the dispute, but the harder test is SRT adoption. Can reimbursement momentum turn into durable medtech growth?
Can Mabwell’s anti-IL-11 antibody redefine scarring treatment through fibrosis reversal?
Mabwell doses first patient in Phase II trial of IL-11 antibody for pathological scarring. Find out what this means for fibrosis drug development.